Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study

Andrea Kuemmerle, Caecilia Schmid, Sonja Bernhard, Victor Kande, Wilfried Mutombo, Medard Ilunga, Ismael Lumpungu, Sylvain Mutanda, Pathou Nganzobo, Digas Ngolo Tete, Mays Kisala, Christian Burri, Severine Blesson, Olaf Valverde Mordt, Andrea Kuemmerle, Caecilia Schmid, Sonja Bernhard, Victor Kande, Wilfried Mutombo, Medard Ilunga, Ismael Lumpungu, Sylvain Mutanda, Pathou Nganzobo, Digas Ngolo Tete, Mays Kisala, Christian Burri, Severine Blesson, Olaf Valverde Mordt

Abstract

Background: Nifurtimox-eflornithine combination therapy (NECT) for the treatment of second stage gambiense human African trypanosomiasis (HAT) was added to the World Health Organization's Essential Medicines List in 2009 after demonstration of its non-inferior efficacy compared to eflornithine therapy. A study of NECT use in the field showed acceptable safety and high efficacy until hospital discharge in a wide population, including children, pregnant and breastfeeding women, and patients with a HAT treatment history. We present here the effectiveness results after the 24-month follow-up visit.

Methodology/principal findings: In a multicenter, open label, single arm phase IIIb study, second stage gambiense HAT patients were treated with NECT in the Democratic Republic of Congo. Clinical cure was defined 24 months after treatment as survival without clinical and/or parasitological signs of HAT. Of the 629 included patients, 619 (98.4%) were discharged alive after treatment and were examined for the presence of trypanosomes, white blood cell count in cerebro-spinal fluid, and disease symptoms. The clinical cure rate of 94.1% was comparable for all subpopulations analyzed at the 24-month follow-up visit. Self-reported adverse events during follow-up were few and concerned mainly nervous system disorders, infections, and gastro-intestinal disorders. Overall, 28 patients (4.3%) died during the course of the trial. The death of 16 of the 18 patients who died during the follow-up period was assessed as unlikely or not related to NECT. Within 24 months, eight patients (1.3%) relapsed and received rescue treatment. Sixteen patients were completely lost to follow-up.

Conclusions/significance: NECT treatment administered under field conditions was effective and sufficiently well tolerated, no major concern arose for children or pregnant or breastfeeding women. Patients with a previous HAT treatment history had the same response as those who were naïve. In conclusion, NECT was confirmed as effective and appropriate for use in a broad population, including vulnerable subpopulations.

Trial registration: The trial is registered at ClinicalTrials.gov, number NCT00906880.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Flow diagram of the study…
Fig 1. Flow diagram of the study population Screening flowchart is shown in the in-hospital publication [15].

References

    1. Büscher P, Cecchi G, Jamonneau V, Priotto G. Human African trypanosomiasis. The Lancet. 2017;390: 2397–2409. doi: 10.1016/S0140-6736(17)31510-6
    1. Franco JR, Simarro PP, Diarra A, Jannin JG. Epidemiology of human African trypanosomiasis. Clin Epidemiol. 2014;6: 257–275. doi: 10.2147/CLEP.S39728
    1. Lumbala C, Simarro PP, Cecchi G, Paone M, Franco JR, Kande Betu Ku Mesu V, et al.. Human African trypanosomiasis in the Democratic Republic of the Congo: disease distribution and risk. Int J Health Geogr. 2015;14: 20. doi: 10.1186/s12942-015-0013-9
    1. Franco JR, Simarro PP, Diarra A, Ruiz-Postigo JA, Jannin JG. The journey towards elimination of gambiense human African trypanosomiasis: not far, nor easy. Parasitology. 2014;141: 748–760. doi: 10.1017/S0031182013002102
    1. Franco JR, Cecchi G, Priotto G, Paone M, Diarra A, Grout L, et al.. Monitoring the elimination of human African trypanosomiasis at continental and country level: Update to 2018. PLoS Negl Trop Dis. 2020;14(5): e0008261. doi: 10.1371/journal.pntd.0008261
    1. Balasegaram M, Young H, Chappuis F, Priotto G, Raguenaud ME, Checchi F. Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Medecins Sans Frontieres programmes. Trans R Soc Trop Med Hyg. 2009;103: 280–90. doi: 10.1016/j.trstmh.2008.09.005
    1. Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U, et al.. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet. 2009;374: 56–64. doi: 10.1016/S0140-6736(09)61117-X
    1. WHO Model Lists of Essential Medicines, 16th list. 2010. Available:
    1. WHO Model Lists of Essential Medicines for children, 4th list. 2013. Available:
    1. Deeks ED. Fexinidazole: First Global Approval. Drugs. 2019;79: 215–220. doi: 10.1007/s40265-019-1051-6
    1. Mesu VKBK, Kalonji WM, Bardonneau C, Mordt OV, Blesson S, Simon F, et al.. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. The Lancet. 2018;391: 144–154. doi: 10.1016/S0140-6736(17)32758-7
    1. Pelfrene E, Allchurch MH, Ntamabyaliro N, Nambasa V, Ventura FV, Nagercoil N, et al.. The European Medicines Agency’s scientific opinion on oral fexinidazole for human African trypanosomiasis. PLoS Negl Trop Dis. 2019;13: e0007381. doi: 10.1371/journal.pntd.0007381
    1. WHO interim guidelines for the treatment of gambiense human African trypanosomiasis. 2019. Available:
    1. Lindner AK, Lejon V, Chappuis F, Seixas J, Kazumba L, Barrett MP, et al.. New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice. Lancet Infect Dis. 2020;20: e38–e46. doi: 10.1016/S1473-3099(19)30612-7
    1. Schmid C, Kuemmerle A, Blum J, Ghabri S, Kande V, Mutombo W, et al.. In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness. PLoS Negl Trop Dis. 2012;6: e1920. doi: 10.1371/journal.pntd.0001920
    1. Kuemmerle A, Schmid C, Kande V, Mutombo W, Ilunga M, Lumpungu I, et al.. Prescription of concomitant medications in patients treated with Nifurtimox Eflornithine Combination Therapy (NECT) for T.b. gambiense second stage sleeping sickness in the Democratic Republic of the Congo. PLoS Negl Trop Dis. 2020;14: e0008028. doi: 10.1371/journal.pntd.0008028
    1. Recommendations of the informal consultation on issues for clinical product development for human African trypanosomiasis (2007). Available:
    1. Kansiime F, Adibaku S, Wamboga C, Idi F, Kato CD, Yamuah L, et al.. A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda. Parasit Vectors. 2018;11. doi: 10.1186/s13071-018-2634-x
    1. Priotto G, Fogg C, Balasegaram M, Erphas O, Louga A, Checchi F, et al.. Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clin Trials. 2006;1: e39. doi: 10.1371/journal.pctr.0010039
    1. Checchi F, Piola P, Ayikoru H, Thomas F, Legros D, Priotto G. Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series. PLoS Negl Trop Dis. 2007;1: e64. doi: 10.1371/journal.pntd.0000064
    1. Alirol E, Schrumpf D, Amici Heradi J, Riedel A, de Patoul C, Quere M, et al.. Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;56: 195–203. doi: 10.1093/cid/cis886
    1. Franco JR, Simarro PP, Diarra A, Ruiz-Postigo JA, Samo M, Jannin JG. Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis. Res Rep Trop Med. 2012;3: 93–101. doi: 10.2147/RRTM.S34399
    1. VanNieuwenhove S. Advances in sleeping sickness therapy. Ann Soc Belg Med Trop 1992;72:39–51.
    1. Milord F, Loko L, Ethier L,Mpia B, Pepin J. Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg 1993;87:473–7. doi: 10.1016/0035-9203(93)90044-q
    1. Priotto G, Pinoges L, Fursa IB, Burke B, Nicolay N, Grillet G, Hewison C, Balasegaram M. Safety and efficacy of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. BMJ 2008;336(7646):705–8. doi: 10.1136/
    1. Implementing the WHO Roadmap on neglected tropical diseases–partners celebrate five years of collaboration (2017). Available:

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться